Áttétes emlőrák: vizsgálatok itt: India
7 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleSaruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- Where
- Delhi, Kolkata, Lucknow, Mumbai, Mysuru, Nagpur, Nashik, New Delhi, Surat, Thiruvananthapuram
- Életkor
- 18 év and over
- People
- 788 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06380751 · EU 2023-504180-16-00 - 3. fázisTaking peopleA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Where
- Bengaluru, Bhubaneswar, Gurugram, Jaipur, Mumbai, Nashik, Pune, Surat, Thane
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Pfizer
See details and how to joinNCT07062965 · EU 2025-520566-22-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Where
- Ahmedabad, Gurugram, Kolkata, Mumbai, Nagpur, NEW Delhi Delhi, Surat
- Életkor
- 18 év and over
- People
- 230 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05894239 · EU 2022-502046-28-00 - 3. fázisTaking peopleA Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Where
- Mumbai, New Delhi
- Életkor
- 18 év and over
- People
- 1200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06312176 · EU 2023-504918-29-00 - No phaseTaking peopleEORTC Metastatic Breast Cancer Module Development
- Where
- Mumbai
- Életkor
- 18 év and over
- People
- 568 worldwide
- Run by
- University of Leeds
See details and how to joinNCT07806266 - 1/2. fázisNot yet taking people in IndiaSafety and Efficacy of Ga68-IAC PET/CT for Diagnosis and Clinical Management in Metastatic Breast Cancer Patients
- Where
- Chandigarh, New Delhi
- Életkor
- 18 év to 80 év
- People
- 25 worldwide
- Run by
- Advanced Imaging Projects, LLC
See details and how to joinNCT04480619 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
- Where
- Vadodara
- Életkor
- 18 év to 65 év
- People
- 657 worldwide
- Run by
- Jina Pharmaceuticals Inc.
See details and how to joinNCT03671044